Sarah Premji

Dr. Wander is a medical oncologist at the Massachusetts General Hospital with a clinical and translational research interest in breast cancer and cancer genomics. He serves as the Director of Translational Research for the Breast Oncology Program, where he leads a multidisciplinary team focused upon leveraging genetic and molecular sequencing results to understand how cancers become resistant to standard therapies in order to develop novel, personalized treatment strategies. Dr. Wander has published more than seventy peer-reviewed manuscripts in the field of precision medicine and continues to present educational sessions and original research nationally and internationally related to drug resistance and the development of personalized therapy for breast cancer. He is an Assistant Professor of Medicine at Harvard Medical School and remains engaged in teaching medical students, residents, and fellows. He was a recipient of the 2017 Dana-Farber Cancer Institute Wong Family Translational Research Award and a 2018 recipient of the American Society of Clinical Oncology Young Investigator Award. As the Director of Precision Medicine in the Termeer Center for Targeted Therapies, he leads efforts across the MGH Cancer Center to promote novel and innovative research leveraging emerging genetic sequencing technologies to both understand resistance to cancer therapies and inform the design of new clinical trials. Dr. Wander's research has helped to shape our understanding of drug resistance in metastatic breast cancer, and he continues to lead a variety of clinical trials, across all phases of drug development, focused upon developing new, personalized treatment options for patients with breast cancer.

Dr. Sarah Premji joined Sarah Cannon Research Institute as Assistant Director of Breast Cancer Research and Medical Oncologist at Sarah Cannon Research Institute Oncology Partners in September 2025.

Dr. Premji completed medical school at the Medical College of Georgia, residency at Baylor College of Medicine and fellowship at Mayo Clinic. Her research interest is breast oncology therapeutics with a focus on patient reported outcomes and treatment toxicity in clincial trials. She attended the prestigous ASCO/AACR Methods in Clinical Cancer Research, formerly known as Vail Workshop and was awarded a ASCO Concur Cancer Young Investigator Award in 2025. While in fellowship, she was awarded Minnesota Society of Clinical Oncology's "outstanding fellow" award, was recognised at San Antonio Breast Cancer Symposium for a clinical scholar award and received a Mayo Clinic small grant award. Dr. Premji was also awarded scholarships to attend numerous workshops including the Duke Southeastern Fellows Research Retreat, NCCN Oncology Fellows Program, Lynn Sage Symposium, Translational Breast Cancer Research Consortium and Alliance.